Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia: target attainment requires further increase of intensity
Familial hypercholesterolemia (FH) causes premature cardiovascular disease (CVD). Lipoprotein apheresis (LA) is recommended as first-line lipid-lowering treatment (LLT) for homozygous (ho) FH.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
3 March 2018
|
| In: |
Pediatric nephrology
Year: 2018, Volume: 33, Issue: 7, Pages: 1199-1208 |
| ISSN: | 1432-198X |
| DOI: | 10.1007/s00467-018-3906-6 |
| Online Access: | Resolving-System, Volltext: https://doi.org/10.1007/s00467-018-3906-6 Verlag: https://link.springer.com/article/10.1007%2Fs00467-018-3906-6 
|
| Author Notes: | Günter Klaus, Christina Taylan, Rainer Büscher, Claus Peter Schmitt, Lars Pape, Jun Oh, Joenna Driemeyer, Matthias Galiano, Jens König, Carsten Schürfeld, Ralf Spitthöver, Juergen R. Schaefer, Lutz T. Weber, Andreas Heibges, Reinhard Klingel |
| Summary: | Familial hypercholesterolemia (FH) causes premature cardiovascular disease (CVD). Lipoprotein apheresis (LA) is recommended as first-line lipid-lowering treatment (LLT) for homozygous (ho) FH. |
|---|---|
| Item Description: | Gesehen am 28.10.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1432-198X |
| DOI: | 10.1007/s00467-018-3906-6 |